Background: We investigated the role of A2B-adenosine receptor in regulating immunosuppressive metabolic stress in the tumor microenvironment. Novel A2B-adenosine receptor antagonist PBF-1129 was tested for antitumor activity in mice and evaluated for safety and immunologic efficacy in a phase I clinical trial of patients with non-small cell lung cancer.
Methods: The antitumor efficacy of A2B-adenosine receptor antagonists and their impact on the metabolic and immune tumor microenvironment were evaluated in lung, melanoma, colon, breast, and epidermal growth factor receptor-inducible transgenic cancer models. Employing electron paramagnetic resonance, we assessed changes in tumor microenvironment metabolic parameters, including pO2, pH, and inorganic phosphate, during tumor growth and evaluated the immunologic effects of PBF-1129, including its pharmacokinetics, safety, and toxicity, in patients with non-small cell lung cancer.
Results: Levels of metabolic stress correlated with tumor growth, metastasis, and immunosuppression. Tumor interstitial inorganic phosphate emerged as a correlative and cumulative measure of tumor microenvironment stress and immunosuppression. A2B-adenosine receptor inhibition alleviated metabolic stress, downregulated expression of adenosine-generating ectonucleotidases, increased expression of adenosine deaminase, decreased tumor growth and metastasis, increased interferon γ production, and enhanced the efficacy of antitumor therapies following combination regimens in animal models (anti-programmed cell death 1 protein vs anti-programmed cell death 1 protein plus PBF-1129 treatment hazard ratio = 11.74 [95% confidence interval = 3.35 to 41.13], n = 10, P < .001, 2-sided F test). In patients with non-small cell lung cancer, PBF-1129 was well tolerated, with no dose-limiting toxicities; demonstrated pharmacologic efficacy; modulated the adenosine generation system; and improved antitumor immunity.
Conclusions: Data identify A2B-adenosine receptor as a valuable therapeutic target to modify metabolic and immune tumor microenvironment to reduce immunosuppression, enhance the efficacy of immunotherapies, and support clinical application of PBF-1129 in combination therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637048 | PMC |
| http://dx.doi.org/10.1093/jnci/djad091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Activation of PLCβ enzymes by G and G proteins is a common mechanism to trigger cytosolic Ca increase. We and others reported that G inhibitor FR900358 (FR) can inhibit both and G - and, surprisingly, G -mediated intracellular Ca mobilization. Thus, the G -G -PLCβ-Ca signaling axis depends entirely on the presence of active G , which reasonably explained FR-inhibited G -induced Ca release.
View Article and Find Full Text PDFSpatially restricted ecto-5'-nucleotidase expression promotes the growth of uterine leiomyomas by modulating Akt activity.
FASEB J
October 2024
Department of Obstetrics & Gynecology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Article Synopsis
- - Uterine leiomyomas, affecting up to 80% of women, cause issues like abnormal bleeding, pelvic pain, and infertility, but their growth mechanisms are not well understood.
- - Research showed that uterine leiomyomas had lower levels of CD73 expression and adenosine compared to healthy myometrium, suggesting a link to tumor growth regulation.
- - Experiments indicated that adding adenosine or certain receptor agonists inhibited the growth of leiomyoma cells by promoting cell death and reducing key protein expressions, proposing new treatment approaches for these tumors.
Adenosine A2B receptor activation regulates the balance between T helper 17 cells and regulatory T cells, and inhibits regulatory T cells exhaustion in experimental autoimmune myositis.
J Cachexia Sarcopenia Muscle
December 2024
Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Wuhou District, China.
Article Synopsis
- Idiopathic inflammatory myopathy (IIM) is an autoimmune disease that affects skeletal muscles, and this study focused on how adenosine receptor signaling impacts the development of experimental autoimmune myositis (EAM) in mice.
- Various treatments, including a CD73 inhibitor and adenosine receptor agonists, were tested on both EAM mice and isolated immune cells to see their effects on muscle injury and inflammation.
- Results showed that patients with IIM had increased levels of enzymes related to adenosine, and using certain treatments could either worsen or improve muscle damage, highlighting the complex role of adenosine pathways in this disease.
Dual A2A/A2B Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth In Vivo.
Mol Cancer Ther
November 2024
EMD Serono, Billerica, Massachusetts.
While A2A adenosine receptor (AR) was considered as a major contributor to adenosine-mediated immunosuppression, A2B, having the lowest affinity to adenosine, has also emerged as a potential contributor to tumor promotion. Therefore, in adenosine-rich tumor microenvironment (TME), where A2B could be complementary and/or compensatory to A2A, simultaneous targeting of A2A and A2B ARs can provide higher potential for cancer immunotherapy. We developed M1069-a highly selective dual antagonist of the A2A and A2B AR.
View Article and Find Full Text PDFUnlocking the adenosine receptor mechanism of the tumour immune microenvironment.
Front Immunol
July 2024
Key Laboratory of Cell Biology, Department of Cell Biology, Ministry of Public Health and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, China.
The suppressive tumour microenvironment significantly hinders the efficacy of immunotherapy in treating solid tumors. In this context, stromal cells, such as tumour-associated fibroblasts, undergo changes that include an increase in the number and function of immunosuppressive cells. Adenosine, a factor that promotes tumour growth, is produced from ATP breakdown and is markedly elevated in the tumour microenvironment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!